MAP Pharmaceuticals Company Profile (NASDAQ:MAPP)

About MAP Pharmaceuticals (NASDAQ:MAPP)

MAP Pharmaceuticals logoMAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MAPP
  • CUSIP: N/A
  • Web: N/A
P/E:
  • Trailing P/E Ratio:
  • P/E Growth:
Dividend:
  • Dividend Yield: 1.0%
 
Frequently Asked Questions for MAP Pharmaceuticals (NASDAQ:MAPP)

What is MAP Pharmaceuticals' stock symbol?

MAP Pharmaceuticals trades on the NASDAQ under the ticker symbol "MAPP."

Who are some of MAP Pharmaceuticals' key competitors?

How do I buy MAP Pharmaceuticals stock?

Shares of MAP Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MAP Pharmaceuticals' stock price today?

One share of MAP Pharmaceuticals stock can currently be purchased for approximately $24.98.


MarketBeat Community Rating for MAP Pharmaceuticals (NASDAQ MAPP)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about MAP Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MAP Pharmaceuticals (NASDAQ:MAPP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for MAP Pharmaceuticals (NASDAQ:MAPP)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for MAP Pharmaceuticals (NASDAQ:MAPP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for MAP Pharmaceuticals (NASDAQ:MAPP)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for MAP Pharmaceuticals (NASDAQ:MAPP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MAP Pharmaceuticals (NASDAQ:MAPP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for MAP Pharmaceuticals (NASDAQ:MAPP)
Latest Headlines for MAP Pharmaceuticals (NASDAQ:MAPP)
Source:
No headlines for this company have been tracked by MarketBeat.com

Social

Chart

MAP Pharmaceuticals (MAPP) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff